"Injections, Subcutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
| Descriptor ID |
D007279
|
| MeSH Number(s) |
E02.319.267.530.620
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Injections, Subcutaneous".
Below are MeSH descriptors whose meaning is more specific than "Injections, Subcutaneous".
This graph shows the total number of publications written about "Injections, Subcutaneous" by people in this website by year, and whether "Injections, Subcutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Injections, Subcutaneous" by people in Profiles.
-
Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis. Ann Pharmacother. 2024 Apr; 58(4):391-397.
-
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022 Nov; 24(6):699-714.
-
Application of Machine Learning to Assess Interindividual Variability in Rapid-Acting Insulin Responses After Subcutaneous Injection in People With Type 1 Diabetes. Can J Diabetes. 2022 Apr; 46(3):225-232.e2.
-
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis. Ann Pharmacother. 2022 05; 56(5):572-581.
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
-
An open-label study evaluating the efficacy of abatacept in alopecia areata. J Am Acad Dermatol. 2021 Mar; 84(3):841-844.
-
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2187-2196.
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
-
Safety of Intradermal/Subcutaneous Lidocaine With Epinephrine Use in Dermatologic Surgery. Dermatol Surg. 2020 01; 46(1):26-30.
-
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 2019 06 25; 3(12):1815-1825.